BFEC
FLGT icon

Benjamin F. Edwards & Company’s Fulgent Genetics FLGT Stock Holding History

Benjamin F. Edwards & Company’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$1K Hold
39
– – ﹤0.01% 2091
2024
Q1 		$1K Hold
39
– – ﹤0.01% 2076
2023
Q4 		$1K Sell
39
-45
-54% -$1.2K ﹤0.01% 2035
2023
Q3 		$2K Hold
84
– – ﹤0.01% 1669
2023
Q2 		$3K Hold
84
– – ﹤0.01% 1628
2023
Q1 		$3K Sell
84
-500
-86% -$16.1K ﹤0.01% 1630
2022
Q4 		$17K Hold
584
– – ﹤0.01% 1309
2022
Q3 		$22K Buy
584
+500
+595% +$25.1K ﹤0.01% 1230
2022
Q2 		$5K Hold
84
– – ﹤0.01% 1538
2022
Q1 		$5K Hold
84
– – ﹤0.01% 1525
2021
Q4 		$8K Hold
84
– – ﹤0.01% 1430
2021
Q3 		$8K Sell
84
-100
-54% -$9.09K ﹤0.01% 1425
2021
Q2 		$17K Hold
184
– – ﹤0.01% 1258
2021
Q1 		$18K Buy
184
+100
+119% +$10.3K ﹤0.01% 1225
2020
Q4 		$4K Buy
+84
New +$3.51K ﹤0.01% 1445

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $4.41B AUM 90.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Benjamin F. Edwards & Company's FLGT Position: Q2 2024 in Review

Benjamin F. Edwards & Company held its Fulgent Genetics (FLGT) position steady in Q2 2024 at 39 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

Benjamin F. Edwards & Company first reported a position in FLGT in Q4 2020 and has held it in 15 quarters since. The position peaked at $22K in Q3 2022. 174 funds tracked by Wall St. Rank hold FLGT as of Q2 2024.

  • Benjamin F. Edwards & Company held 39 shares of Fulgent Genetics worth $1K as of Q2 2024.
  • Benjamin F. Edwards & Company left its Fulgent Genetics share count unchanged in Q2 2024.
  • Fulgent Genetics made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #2091 holding.
  • Benjamin F. Edwards & Company first reported a position in Fulgent Genetics in Q4 2020 and has held it in 15 quarters since.
  • Benjamin F. Edwards & Company's Fulgent Genetics position peaked at $22K in Q3 2022.
  • 174 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.